Abstract:Introduction: Evasion of the immune system is a hallmark of cancer and understanding immune escape mechanisms has led to the development of immunotherapies to boost anti-tumor immunity. CD47 is an immunosuppressive protein that transduces a "don't eat me" signal when bound to the SIRPα receptor on antigen presenting cells (APCs). Cancer cells exploit CD47 to block phagocytosis by APCs and dampen anti-tumor immune responses. Various inhibitors of the CD47-SIRPα signaling axis, including monoclonal antibodies, have been developed as immunotherapeutic agents for administering CD47 blockade in cancer patients, and are currently being evaluated in clinical trials. Understanding mechanisms of tumor resistance to CD47-targeted immunotherapy will guide its clinical development and could inform rational combination therapies to enhance its efficacy. Since CD47 is prognostically and functionally relevant in non-small cell lung cancer (NSCLC), we investigated the response of two syngeneic, murine lung cancer models to CD47 loss-of-function (LOF). Methods: CRISPR/Cas9 was used to knockout (KO) CD47 in two murine (LLC, CMT167) syngeneic models of NSCLC. Tumor growth studies were conducted in immune competent (C57BL/6) mice orthotopically implanted with wildtype (WT) or CD47 KO cells. Immunophenotyping of tumors was done prior to humane endpoints using flow cytometry to compare immune cell infiltration in WT versus CD47 KO tumors to assess lung tumor response to CD47 LOF. Results: Survival analyses of immunocompetent hosts with orthotopic LLC and CMT tumors revealed that mice with CD47 KO tumors lived longer than those with WT tumors, although CD47 KO tumors were ultimately lethal. Tumor immunophenotyping revealed higher frequencies of MHC-IIhighCD80+ M1 macrophages and activated cytotoxic CD69+CD8+ T cells in CD47 KO tumors compared to WT. Moreover, the percentage of PD-L1+ tumor and myeloid cells was greater in CD47 KO tumors compared to WT tumors, suggesting PD-L1 may be upregulated on various cell types in the TME as a compensation mechanism when CD47 is inhibited. Conclusion: Consistent with the literature, our findings show that CD47 LOF in lung cancer cells prolongs the survival of tumor-bearing mice and promotes infiltration of anti-tumor immune cells in two orthotopic, syngeneic NSCLC models. Upregulation of PD-L1 in cancer and myeloid cells from CD47 KO tumors was also observed, revealing a putative PD-L1-driven mechanism of resistance to CD47 blockade. Although additional preclinical and clinical studies are needed to confirm the generalizability of our observations and to validate them in patients treated with CD47-targeted therapy, our findings provide evidence to support continued development of approaches for combining CD47 and PD-L1 blockade as an effective immunotherapeutic strategy for the treatment of NSCLC. Citation Format: Asa P.Y Lau, Kelsie L Thu. Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B007.

Localized CD47 blockade enhances immunotherapy for murine melanoma

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

The landscape overview of CD47-based immunotherapy for hematological malignancies

Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response

Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

CD47 Blockade Triggers T Cell–mediated Destruction of Immunogenic Tumors

Deciphering the role of CD47 in cancer immunotherapy

Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer

Engineered CD47 protects T cells for enhanced antitumour immunity

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma

Preclinical development of SGN-CD47M: Protease-activated antibody technology enables selective tumor targeting of the innate immune checkpoint receptor CD47

Dual targeting of CTLA-4 and CD47 on T<sub>reg</sub> cells promotes immunity against solid tumors

The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment

Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies